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 Observational data suggests taller people have a higher risk of venous thromboembolism 
(VTE). 
 We used Mendelian randomization techniques to further explore this association in three 
studies. 
 Risk of VTE increased by 30–40% for each 10 cm increment in height. 
 Height was more strongly associated with deep vein thrombosis than with pulmonary 
embolism. 
 
Summary. Background: Taller height is associated with greater risk of venous 
thromboembolism (VTE). Objectives: We used instrumental variable (IV) techniques 
(Mendelian randomization) to further explore this relationship. Methods: Participants of 
European ancestry were included from two cohort studies [Atherosclerosis Risk in Communities 
(ARIC) study and Cardiovascular Health Study (CHS)] and one case-control study [Mayo Clinic 
VTE Study (Mayo)]. We created two weighted genetic risk scores (GRS) for height; the full 
GRS included 668 single nucleotide polymorphisms (SNPs) from a previously published meta-
analysis and the restricted GRS included a subset of 362 SNPs not associated with weight 
independently of height. Standard logistic regression and IV models were used to estimate odds 
ratios (ORs) for VTE per 10 cm increment in height. ORs were pooled across the three studies 
using inverse variance weighted random effects meta-analysis. Results: Among 9143 ARIC and 
3180 CHS participants free of VTE at baseline, there were 367 and 109 incident VTE events. 
There were 1143 VTE cases and 1292 controls included from Mayo. The pooled ORs from non-
IV models and models using the full and restricted GRSs as IVs were 1.27 (95% CI: 1.11, 1.46), 
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1.34 (95% CI: 1.04, 1.73), and 1.45 (95% CI: 1.04, 201) per 10 cm greater height, respectively. 
Conclusions: Taller height is associated with an increased risk of VTE in adults of European 
ancestry. Possible explanations for this association, including that taller people may have greater 
venous surface area, greater number of venous valves, or greater hydrostatic pressure, need to be 
explored further.  
 








Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary 
embolism (PE), occurs in 350 000 to 600 000 people and contributes to over 100 000 deaths in 
the U.S. each year [1]. Taller adult height is associated with greater risk of VTE [2–11]. For 
example, the Longitudinal Investigation of Thromboembolism Etiology (LITE) found that each 
6.3 cm increment in height was independently associated with a 1.14 (95% confidence interval 
1.05, 1.24) greater risk of VTE [9]. The physiologic explanation underpinning this increased risk 
is not yet fully understood; some proposed mechanisms include greater venous surface area, 
greater number of venous valves, and greater hydrostatic pressure in taller people [9].  
It is possible that uncontrolled confounding by other risk factors explains the association of 
height with VTE, so additional techniques in causal inference would be useful to pursue. 
Genome-wide association studies have found many genetic variants related to height [12–20]. 
The most recent meta-analysis by Wood et al. found that 697 single nucleotide polymorphisms 
(SNPs) explained 20% of the heritability (and 16% of the overall variance) of height [20]. The 
high amount of variance in height explained by these SNPs, which should not be influenced by 
traditional confounding factors or by reverse causality, provides a unique opportunity to apply 
Mendelian randomization methods to explore the relationship between height and VTE. We used 
SNPs from the Wood et al. meta-analysis [20] as an instrumental variable (IV) for height, 
allowing us to better estimate the association between height and risk of VTE. We implemented 
these techniques in three separate studies (Atherosclerosis Risk in Communities study, the 
Cardiovascular Health Study, and the Mayo Clinic VTE Study) and then combined these results 





The Longitudinal Investigation of Thromboembolism Etiology (LITE) is a combination of 
two population-based cohort studies: the Atherosclerosis Risk in Communities (ARIC) study 
[21] and the Cardiovascular Health Study (CHS) [22]. The study design and methods of LITE 
were described previously [23,24]. Briefly, ARIC began in 1987-89 with enrollment of 15 792 
men and women aged 45 to 64 years, who were predominately black or white, and held follow-
up examinations in 1990-92, 1993-95, 1996-98, and 2011-13, in addition to yearly telephone 
contact. CHS began in 1989-1990 with enrollment of 5201 mostly white men and women aged 
≥65 years; an additional 687 African Americans were enrolled in CHS in 1992-93. Over the first 
10 years of the study, participants in CHS were contacted every 6 months with either a telephone 
interview or clinic visit, and then by telephone interview every 6 months thereafter. The Mayo 
Clinic VTE Study (Mayo) is a case-control study of outpatients, including VTE cases referred to 
Mayo Clinic (n=1488) and controls undergoing general medical examinations at Mayo Clinic 
(n=1439). Cases and controls were selected for study participation from 1994-2009 and 2004-
2009, respectively, using frequency matching on age, sex, state of residence, and prior 
myocardial infarction and stroke status [25]. Each study was approved by the institutional review 
board of its participating study center, and all participants provided written informed consent.  
 
Height and Covariate Measurement 
Baseline standing height was measured by trained technicians with participants standing as 
straight as possible without shoes and with back and heels against a vertical mounted centimeter 
ruler, to the nearest centimeter (cm) in ARIC and nearest half-cm in CHS. Weight was measured 
using a balance scale. Body mass index (BMI) was calculated as weight (in kilograms) divided 
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by height (in meters) squared. Waist circumference was measured at the level of the umbilicus to 
the nearest cm. In order to confirm that potential confounders were not associated with the IV for 
height (a necessary assumption of a valid IV), we additionally consider other measured risk 
factors for VTE. Blood samples were drawn by staff and blood measurements were performed in 
study-specific central laboratories. Diabetes was defined as fasting blood glucose ≥7 mmol/L 
(≥126 mg/dL), non-fasting blood glucose ≥11.1 mmol/L (≥200 mg/dL), a self-reported 
physician’s diagnosis of diabetes, or reported use of a diabetes medication. Glomerular filtration 
rate was estimated from creatinine using an existing algorithm [26]. Factor VIII and activated 
partial thromboplastin time (available in ARIC only) were assessed as previously described 
[27,28]. C-reactive protein was measured via high-sensitivity immunoassay using Visit 2 (1990-
92) plasma samples in ARIC [29] and baseline plasma samples in CHS [30]. In Mayo, height and 
weight were ascertained by self-report at the time of study enrollment for both cases and 
controls, and BMI was calculated as weight (in kilograms) divided by height (in meters) squared. 
 
VTE Occurrence 
Hospitalizations were identified by participants or proxy reports during annual contact by 
phone in ARIC and semi-annual contact by phone or clinic visit in CHS. Additional 
hospitalizations were found in ARIC through 2011 and CHS through 2001 by surveillance of 
local hospital discharge lists and Medicare records, respectively. Copies of hospital records were 
obtained for hospitalizations with International Classification of Disease (ICD) discharge codes 
indicating possible VTE events [23]. Validation of VTE events was performed by two physicians 
using standardized criteria requiring positive imaging tests for diagnosis of DVT and PE [23]. 
VTE events in Mayo were initially identified by a physician in the hematology clinic and 
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validated by presence of imaging tests or by pathological examination of a surgically removed 
thrombus, as described previously [25]. DVT events in ARIC and CHS were restricted to those 
occurring in the lower extremity or vena cava. DVT events in Mayo also included those 
occurring in the arm. 
 
Genotyping and Imputation 
Details on genotyping, quality control, and imputation have been described previously [31–
33]. Briefly, genotyping was performed in ARIC, CHS, and Mayo using the Affymetrix 6.0, 
Illumina 370CNV, and Illumina Human 660W Quad genome-wide SNP arrays, respectively. 
Before imputation, samples were filtered based on call rates, and SNPs were filtered based on 
call rates, mean allele frequencies, and Hardy Weinberg equilibrium P-values (see Table S1). 
Imputation to ≈2.5 million autosomal SNPs in the HapMap Phase II sample of European 
ancestry (CEU) was performed using MACH [34] v1.0.16 in ARIC and Mayo and BIMBAM 
[35] v0.99 in CHS.  
 
Genetic Instrument for Height 
The 697 height-related SNPs and their respective weights used for creating the weighted 
genetic risk score (GRS) IV were obtained from a genome-wide association meta-analysis study 
of height in 253 288 people of European ancestry [20]. This meta-analysis was performed using 
only the SNPs in the HapMap II sample; since 8 of the SNPs were unavailable in the 1000 
Genomes reference panel, we too elected to use SNPs from HapMap II. The SNP weights are 
external to Mayo but are not external to ARIC and CHS since the two latter studies were 
included in the original meta-analysis [together ARIC and CHS comprised 11 338 (4.5%) of the 
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total sample of 253 288]. In order to minimize possible linkage disequilibrium among SNPs 
selected for the GRS, we excluded one of two SNPs from any correlated pair of SNPs with r2 > 
0.1 as listed in Supplementary Table 1 from Wood et al. [20] (the first of the two correlated 
SNPs was excluded based on the listed order). We found that 29 SNPs were in possible linkage 
disequilibrium, leaving a total of 668 SNPs with which to create the “full GRS” (see Table S1S2, 
Column A for the list of SNPs used in the full GRS). Exploratory analyses indicated that the full 
GRS was associated with weight, independently of height, in ARIC and CHS (violating a key IV 
assumption); therefore, as a secondary analysis we created a “restricted GRS” that was 
uncorrelated with weight independently of height. The set of SNPs used to create the restricted 
GRS was determined using the ARIC cohort; in linear regression models (separately for each 
SNP), weight was regressed on each SNP and height, and the 306 SNPs showing the most 
statistically significant associations with weight (P < 0.4) independently of height were excluded. 
This alpha level was chosen because it was the smallest cut-off for which the restricted GRS was 
no longer associated with weight independently of height in ARIC. This left a subset of 362 
SNPs (see Table S1S2, Column B for the list of SNPs used in the restricted GRS). Each GRS 
was created by taking ∑(beta value * estimated # of allele copies) over all of the SNPs, using the 
beta values listed in Column G of Supplementary Table 1 from Wood et al. [20]. 
 
Statistical Analysis 
Only persons of European ancestry who provided written informed consent for DNA testing 
were included in this study. In ARIC and CHS respectively, there were 9349 and 3362 eligible 
participants with genotyping data available; we excluded those who had missing height 
information (n = 5 and 6), reported a VTE prior to baseline (n = 160 and 165), or were taking 
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anticoagulants at baseline (n = 41 and 11), leaving a maximum of 9143 and 3180 participants for 
the present analyses, respectively. In Mayo, there were 2522 eligible participants with 
genotyping data available; after excluding those who had missing height information (n = 117) 
there was a maximum of 2435 participants for the present analyses. 
To assess the strength of the GRS IVs, we used the F-statistic from a linear model regressing 
height on the GRS. If the GRS is associated with risk factors for VTE other than height, it would 
violate assumptions necessary for the IV analysis. To assess this, we estimated proportion of 
variance (R2) of each covariate explained by the GRS using linear regression. For Mayo, we only 
used controls to assess the association between covariates and the GRS because VTE is a 
relatively rare disease and we considered the controls to be a better representation of the general 
population compared to the combined group of cases and controls [36].  
To examine the possibility of a nonlinear relationship between height and VTE, we initially 
fit logistic regression models in ARIC with VTE as the outcome and modeling height using 
restricted cubic splines. Since the association between VTE and height was approximately linear 
in the logit scale (see Figure S1), we did not transform height in subsequent analyses. We 
estimated odds ratios (OR) and 95% confidence intervals (CI) for VTE per 10 cm increment in 
height using three separate logistic models. The first model was non-IV logistic regression 
adjusted for age, sex, body mass index, and study site in ARIC and CHS and for age, sex, body 
mass index, Minnesota residence, and history of stroke and myocardial infarction in Mayo. The 
other two models were IV logistic structural mean models via a generalized method of moments 
estimator [37], using the full GRS and restricted GRS as the IVs for height in each respective 
model. Each of these models was fit separately to each of the three datasets. IV models using the 
full GRS and restricted GRS as the IVs were also run for DVT and PE separately. IV models 
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were unadjusted for ARIC and CHS and were adjusted for the study matching variables for 
Mayo. As an alternative to using the restricted GRS IV model, we fit a model using the full GRS 
as the IV and adjusted for weight as a covariate in order to assess the possibility that weight 
mediates the height—VTE association.  
Although using a GRS as an IV typically avoids the problem of weak instrument bias, there 
may still be inconsistent effect estimation by the individual variants comprising the GRS [38]. 
Thus, we performed sensitivity analyses to test for the influence of bias from potential 
directional pleiotropy or heterogeneity of individual SNP IVs using three robust IV methods: 
inverse variance weighted (IVW), MR-Egger regression, and weighted median estimation 
[38,39]. Summary IV estimates and standard errors for each SNP (using the ratio estimator [40]) 
were analyzed using the Stata package mrrobust to obtain robust IV OR estimates for the full and 
restricted set of SNPs for each of the three studies. Evidence for directional pleiotropy or 
heterogeneity of individual IV estimates was assessed by evaluating the I2 index and Q test [41] 
from the IVW analysis and the significance of the intercept term from MR-Egger regression, as 
well as by visual inspection of funnel plots for asymmetry. The standard errors used in the funnel 
plots were estimated using the delta method.[42] 
For each of the three sets of results for the main VTE analysis, four sets of results for the 
DVT and PE analysis, and six sets of results for the sensitivity analysis, inverse variance 
weighted random-effects meta-analysis was performed to obtain a pooled OR and 95% CI across 
the three studies. Analyses were performed in Stata, version 12.1 (ARIC and CHS) and R, 





Baseline characteristics are summarized for ARIC and CHS in Table 1 and for Mayo in 
Table 2. Notably, participants in CHS were on average older and shorter compared with those in 
ARIC and Mayo, and mean BMI was higher in Mayo compared with ARIC and CHS. In each 
study, height was strongly associated with the IVs (all F-statistics >105 and >63 for the full and 
restricted GRS, respectively, where F<10 is indicative of a weak IV [45]; Tables 1 and 2). Other 
anthropometric factors, including BMI, weight, and waist circumference, were also associated 
with the full or restricted GRS IVs (Tables 1 and 2). However, these anthropometric covariates 
were not associated with the restricted GRS IV after adjustment for height (all P-values > 0.2; 
however, adjustment for height could potentially create bias). The GRS IVs also were not 
generally associated with other common VTE risk factors in the three different studies (Tables 1 
and 2). Additionally, a separate GRS for VTE, consisting of 5 SNPs in F5 (Leiden), F2, F11, 
FGG, and ABO genes [46], was not associated with the full or restricted GRS IVs in ARIC 
(R2=0.00; P>0.5).  
Among 9143 ARIC and 3180 CHS participants, there were 367 and 109 incident VTE events 
after 23 and 12 years of follow-up, respectively. There were 1143 VTE cases and 1292 controls 
included from Mayo. Combining the study-specific non-IV logistic regression model results, the 
summary OR for VTE per 10 cm increment in height was 1.27 (95% CI: 1.11, 1.46) with 
moderate heterogeneity between studies (I2=42%, P=0.18; Figure 1). Sex-stratified point 
estimates were similar in men and women in each study and by meta-analysis (all P for 
interaction >0.36, data not shown). The summary ORs obtained by combining study-specific IV 
model results were similar whether using the full GRS IV [OR: 1.34 (95% CI: 1.04, 1.73)] or the 
restricted GRS IV [OR: 1.45 (95% CI: 1.04, 2.01)] with little to no evidence of heterogeneity 
between studies [I2=22% (P=0.28) and I2=0% (P=0.98), respectively; Figure 1]. There was 
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slightly less precision in the estimate of the pooled OR using the restricted GRS IV potentially 
because inclusion of fewer SNPs resulted in a weaker instrument. The summary OR obtained 
from the full GRS IV model additionally adjusted for weight was slightly attenuated [OR: 1.24 
(95% CI: 0.96, 1.61)]. Combining study-specific IV model results using the restricted GRS IV, 
height was associated slightly more strongly with DVT [OR: 1.46 (95% CI: 0.98, 2.16)] than 
with PE [1.20 (0.79, 1.82); see Figure S1S2). 
Sensitivity analyses estimated summary ORs from robust IV analyses that take a weighted 
summary of the individual effects of multiple SNP IVs [OR (95% CI) for IVW, MR-Egger 
regression, and weighted median using the set of 362 restricted SNPs: 1.15 (0.96, 1.39), 1.34 
(0.99, 1.82), and 1.15 (0.87, 1.54), respectively; I2=0 for each model; see Figure S2] were similar 
but slightly attenuated in comparison to the analyses using a single GRS as the IV. Results from 
sensitivity analyses using robust IV estimators that take a weighted summary of the individual 
effects of the SNPs are shown in Figure S3. When using the set of 362 restricted SNPs as 
individual IVs, the summary OR using MR-Egger regression [OR: 1.34 (0.99, 1.82); I2=0] was 
similar to the estimate obtained when using the restricted GRS as a single IV. By comparison, 
the summary ORs using IVW [OR: 1.15 (95% CI: 0.96, 1.39); I2=0] and weighted median [OR: 
1.15 (95% CI: 0.87, 1.54); I2=0] methods were fairly attenuated. Within each study, there was 
little to no evidence of heterogeneity between SNP IVs in the full or restricted set of SNPs in 
IVW models [I2 from 0% to 7%; all Q test P-values ≥ 0.16; see Figures S3S4-S8S9]. Funnel 
plots did not display obvious evidence of heterogeneity or directional pleiotropy using either set 
of SNPs, which was supported by formal testing of MR-Egger regression intercept terms in 
ARIC and Mayo (P-values > 0.2) but not in CHS (P-values ≤ 0.02; see Figures S3S4-S8S9). 
Pooled across studies, the summary MR-Egger regression intercept term did not show evidence 
Formatted: Indent: First line:  0 cm, Add space between
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of directional pleiotropy [intercept: -0.006 (95% CI: -0.020, 0.008) using full set of SNPs and -
0.008 (95% CI: -0.024, 0.007) using restricted set of SNPs].  
Discussion 
In this meta-analysis we found a consistent positive relationship between height and VTE 
whether estimating the association of height with VTE using standard logistic regression and 
adjusting for relevant confounders or using IV analysis with a single weighted GRS, which 
suggested the risk of VTE increased by approximately 30-40% for each 10 cm increment in 
height. Sensitivity analyses using robust IV methods with multiple IVs (i.e., individual SNPs) 
generally supported our main findings; however the associations were attenuated. 
Previous studies have found that taller height is associated with lower risk of most 
cardiovascular disease outcomes and total mortality [10], but taller height is associated with 
higher risk of VTE [2–11], atrial fibrillation [47], and abdominal aortic aneurysm [48]. Previous 
Mendelian randomization analyses provide additional support for an association of taller height 
with lower risk of coronary heart disease [49,50] but not with risk of stroke [49]. To our 
knowledge, this is the first study using Mendelian randomization to identify taller height as a risk 
factor for VTE. 
Vessel wall damage, blood flow changes, and hypercoagulability are the three important 
factors for the pathogenesis of thrombosis [51]. A recent analysis in LITE found that the 
association of height with VTE risk was not mediated by markers of hemostasis or inflammation, 
suggesting that taller height more likely influences VTE risk through greater venous area, venous 
stasis, or vessel wall damage than through hypercoagulability [52]. Taller height is a risk factor 
for various types of cancer [53], another key risk factor for VTE. However, the non-IV OR for 
VTE was unchanged after excluding 112 cancer-provoked VTE cases in ARIC [OR: 1.46 (95% 
Formatted: Font: 10 pt
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CI: 1.18, 1.79) per 10 cm in height], and active cancer was an exclusion criterion in Mayo. Thus, 
it is unlikely that cancer (and its effects on hypercoagulability) acts as a mediator of the 
association between height and VTE. Taller height is associated with higher resting venous 
pressure during quiet standing in healthy people [54]. Over time, this higher pressure could lead 
to more damage to venous walls and thereby greater VTE risk. Also, taller people have a greater 
venous surface area and possibly more venous valves, allowing for a greater area in which 
thrombi can form. Indeed, the majority of thrombi form in valve pockets of the deep veins in 
lower limbs where blood flow is stagnant [55]. This is supported by our finding of a stronger 
association of height with DVT than with PE. 
Our ability to estimate the effect of height on VTE risk depends on the validity of our IV. In 
the context of this study, the three assumptions of a valid IV are that it (1) is associated with 
height, (2) is not associated with any confounder of the height–VTE association, and (3) is 
conditionally independent of VTE given height and confounders. Although we found that 
assumption (1) was satisfied, it is not possible to explicitly confirm assumptions (2) and (3) since 
they involve unmeasured confounders and the function of many of the SNPs used to construct 
the GRS IVs is unknown. Nevertheless, we found that the GRS IVs (particularly the restricted 
GRS) were generally not associated (independently of height) with measured risk factors for 
VTE that could potentially confound the association between height and VTE, which provides 
support for the plausibility of assumption (2). For assumption (3), we assume that the GRS IVs 
are not related to VTE through any pathway other than height [i.e., there is no horizontal 
pleiotropy (also known as biological or type I pleiotropy)] [38,56]. Given the large number of 
SNPs used to construct the GRS IVs, it is difficult to know whether this assumption is 
reasonable. However, to our knowledge, none of the genes containing the 697 height SNPs from 
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the Wood et al. meta-analysis [19] has previously been reported in genome-wide association 
studies of VTE [32,33,57–59], and we found no association between the GRS IVs for height and 
a previously reported 5-SNP GRS for VTE [46]. Beyond the three IV assumptions, two 
additional assumptions need to be met in order to identify the effect using the generalized 
method of moments estimator. First, we assume there is no effect modification (on the 
multiplicative scale) by the IV on the association between height and VTE [60]. There was no 
evidence that this assumption was violated in any of the three studies (all interaction P-values ≥ 
0.52) except in ARIC when using the full GRS IV (interaction P-value = 0.04). Second, we must 
assume the effect of height on VTE is linear on the logit scale and independent of the IV [37], 
which appeared reasonable from restricted cubic spline modeling. 
The main GRS IV and IVW analyses are unbiased only when all IVs are valid. However, the 
MR-Egger regression and weighted median analyses allow for consistent effect estimation with 
some relaxation of IV assumptions, albeit with some loss of precision compared to IVW. 
Specifically, MR-Egger regression allows all IVs to violate assumption (3) provided they meet 
the weaker assumption that any pleiotropic effects of an IV (effects of the IV on VTE through 
pathways other than height) are uncorrelated with the strength of the IV–height association [38], 
while weighted median estimation allows for up to 50% of the weight contributed by IVs to 
violate assumptions (2) and (3) [39]. Summary robust IV effect estimates were slightly 
attenuated compared to estimates from the main IV analysis, which could have possibly resulted 
from using different estimation methods (ratio estimator vs generalized method of moments) and 
different IV weighting schemes. The fact that summary robust IV effect estimates were slightly 
larger when using the restricted set of SNPs may suggest reduced pleiotropy in comparison to 
using the full set of SNPs. 
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Although there was an association between height and risk of VTE in the main meta-
analyzed results overall, in CHS the estimated effect was weak or non-existent and had wide 
confidence intervals. The apparent lack of association in CHS may be partially explained by the 
older age of this cohort, whereby the effect of height is masked in older age when there is a 
higher prevalence of other VTE risk factors, or by selection bias. Other observational studies 
have analogously reported that the effect of family history as a risk factor for VTE gets weaker 
with increasing age [61,62]. 
Strengths of this analysis include using data from three different study populations (two 
population-based prospective studies and one clinic-based case-control study) and having 
validated VTE cases in each study. However, there are some limitations of our study. We only 
included people of European ancestry in order to be consistent with the genome-wide meta-
analysis study of height [20], which limits the generalizability of our results. Further, although 
we have shown that the genetic instrument was not associated with many common VTE risk 
factors (i.e., potential confounders), we were not able to explore the precise physiologic 
mechanisms that may mediate the relationship between height and VTE risk, including that taller 
adults may have greater venous surface area, a greater number of venous valves, and greater 
hydrostatic pressure. Future studies should examine the relationship of height and VTE risk in 
other racial/ethnic groups and further explore the mechanisms connecting taller height with VTE 
risk.  
In summary, this analysis provides evidence that taller height is associated with increased 
risk of VTE in adults of European ancestry. Additionally, we supplement the results of many 
previous studies reporting associations between height and VTE by use of an IV technique that 
allows for effect estimation in a way that may be less influenced by traditional confounding 
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factors than observational analyses. Future research should continue using IV techniques to 
better understand the relationship of other exposures with VTE risk.  
 
Addendum 
A. R. Folsom, M. de Andrade, and M. Cushman acquired the data. N. S. Roetker, S. M. Armasu, 
and T. M. Palmer performed or assisted with the statistical analysis. N. S. Roetker drafted the 
manuscript. S. M. Armasu, J. S. Pankow, P. L. Lutsey, W. Tang, M. A. Rosenberg, T. M. 
Palmer, R. F. MacLehose, S. R. Heckbert, M. Cushman, M. de Andrade, and A. R. Folsom made 
critical comments on the manuscript. All authors read and approved the final manuscript.  
 
Acknowledgments 
The authors thank the staff and participants of the ARIC Study, CHS, and Mayo VTE study 
for their important contributions. 
The National Heart, Lung, and Blood Institute (NHLBI) supported LITE via HL0597367 and 
ARIC via HL59367, HL103706, and contracts HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C.  
CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, 
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, 
N01HC85086, and grants U01HL080295, U01HL130114, and R01 HL059367 from the National 
Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National 
Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by 
R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS 
18 
 
investigators and institutions can be found at CHS-NHLBI.org. The content is solely the 
responsibility of the authors and does not necessarily represent the official views of the National 
Institutes of Health. 
 Mayo was funded, in part, by grants from the National Institutes of Health, National Heart, 
Lung and Blood Institute (HL66216 and HL83141 to JAH) and the National Human Genome 
Research Institute (HG04735) for the Mayo VTE study (MdA and SMA). 
 Additionally, MR is supported by National Heart, Lung, and Blood Institute grant 
1K23HL127296. 
 
Disclosures of Conflicts of Interests 
The authors state that they have no conflict of interest. 
References 
1  Office of the Surgeon General (US), National Heart, Lung, and Blood Institute (US). The 
Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary 
Embolism. Rockville (MD): Office of the Surgeon General (US); 2008.  
2  Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart 
disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975–82.  
3  Pomp ER, le Cessie S, Rosendaal FR, Doggen CJM. Risk of venous thrombosis: obesity and 
its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 
139: 289–96.  
19 
 
4  Lutsey PL, Virnig BA, Durham SB, Steffen LM, Hirsch AT, Jacobs DR, Folsom AR. 
Correlates and consequences of venous thromboembolism: The Iowa Women’s Health 
Study. Am J Public Health 2010; 100: 1506–13.  
5  Rosengren A, Fredén M, Hansson P-O, Wilhelmsen L, Wedel H, Eriksson H. Psychosocial 
factors and venous thromboembolism: a long-term follow-up study of Swedish men. J 
Thromb Haemost 2008; 6: 558–64.  
6  Braekkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen J-B. Body height 
and risk of venous thromboembolism: The Tromsø Study. Am J Epidemiol 2010; 171: 1109–
15.  
7  Severinsen MT, Johnsen SP, Tjønneland A, Overvad K, Dethlefsen C, Kristensen SR. Body 
height and sex-related differences in incidence of venous thromboembolism: a Danish 
follow-up study. Eur J Intern Med 2010; 21: 268–72.  
8  Borch KH, Nyegaard C, Hansen J-B, Mathiesen EB, Njølstad I, Wilsgaard T, Brækkan SK. 
Joint effects of obesity and body height on the risk of venous thromboembolism: the Tromsø 
Study. Arterioscler Thromb Vasc Biol 2011; 31: 1439–44.  
9  Lutsey PL, Cushman M, Heckbert SR, Tang W, Folsom AR. Longer legs are associated with 
greater risk of incident venous thromboembolism independent of total body height. The 




10  Emerging Risk Factors Collaboration. Adult height and the risk of cause-specific death and 
vascular morbidity in 1 million people: individual participant meta-analysis. Int J Epidemiol 
2012; 41: 1419–33.  
11  Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Body height, 
mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost 2015; 13: 
548–54.  
12  Weedon MN, Lettre G, Freathy RM, Lindgren CM, Voight BF, Perry JRB, Elliott KS, 
Hackett R, Guiducci C, Shields B, Zeggini E, Lango H, Lyssenko V, Timpson NJ, Burtt NP, 
Rayner NW, Saxena R, Ardlie K, Tobias JH, Ness AR, et al. A common variant of HMGA2 
is associated with adult and childhood height in the general population. Nat Genet 2007; 39: 
1245–50.  
13  Lettre G, Jackson AU, Gieger C, Schumacher FR, Berndt SI, Sanna S, Eyheramendy S, 
Voight BF, Butler JL, Guiducci C, Illig T, Hackett R, Heid IM, Jacobs KB, Lyssenko V, Uda 
M, Diabetes Genetics Initiative, FUSION, KORA, Prostate, Lung Colorectal and Ovarian 
Cancer Screening Trial, et al. Identification of ten loci associated with height highlights new 
biological pathways in human growth. Nat Genet 2008; 40: 584–91.  
14  Sanna S, Jackson AU, Nagaraja R, Willer CJ, Chen W-M, Bonnycastle LL, Shen H, 
Timpson N, Lettre G, Usala G, Chines PS, Stringham HM, Scott LJ, Dei M, Lai S, Albai G, 
Crisponi L, Naitza S, Doheny KF, Pugh EW, et al. Common variants in the GDF5-UQCC 
region are associated with variation in human height. Nat Genet 2008; 40: 198–203.  
21 
 
15  Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, Mangino M, Freathy RM, 
Perry JRB, Stevens S, Hall AS, Samani NJ, Shields B, Prokopenko I, Farrall M, Dominiczak 
A, Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium, Johnson T, 
Bergmann S, Beckmann JS, et al. Genome-wide association analysis identifies 20 loci that 
influence adult height. Nat Genet 2008; 40: 575–83.  
16  Johansson A, Marroni F, Hayward C, Franklin CS, Kirichenko AV, Jonasson I, Hicks AA, 
Vitart V, Isaacs A, Axenovich T, Campbell S, Dunlop MG, Floyd J, Hastie N, Hofman A, 
Knott S, Kolcic I, Pichler I, Polasek O, Rivadeneira F, et al. Common variants in the JAZF1 
gene associated with height identified by linkage and genome-wide association analysis. 
Hum Mol Genet 2009; 18: 373–80.  
17  Lei S-F, Tan L-J, Liu X-G, Wang L, Yan H, Guo Y-F, Liu Y-Z, Xiong D-H, Li J, Yang T-L, 
Chen X-D, Guo Y, Deng F-Y, Zhang Y-P, Zhu X-Z, Levy S, Papasian CJ, Hamilton JJ, 
Recker RR, Deng H-W. Genome-wide association study identifies two novel loci containing 
FLNB and SBF2 genes underlying stature variation. Hum Mol Genet 2009; 18: 1661–9.  
18  Soranzo N, Rivadeneira F, Chinappen-Horsley U, Malkina I, Richards JB, Hammond N, 
Stolk L, Nica A, Inouye M, Hofman A, Stephens J, Wheeler E, Arp P, Gwilliam R, Jhamai 
PM, Potter S, Chaney A, Ghori MJR, Ravindrarajah R, Ermakov S, et al. Meta-analysis of 
genome-wide scans for human adult stature identifies novel Loci and associations with 
measures of skeletal frame size. PLoS Genet 2009; 5: e1000445.  
19  Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, Willer CJ, 
Jackson AU, Vedantam S, Raychaudhuri S, Ferreira T, Wood AR, Weyant RJ, Segrè AV, 
Speliotes EK, Wheeler E, Soranzo N, Park J-H, Yang J, Gudbjartsson D, et al. Hundreds of 
22 
 
variants clustered in genomic loci and biological pathways affect human height. Nature 
2010; 467: 832–8.  
20  Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan 
J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, 
Fehrmann R, Ferreira T, Jackson AU, Karjalainen J, et al. Defining the role of common 
variation in the genomic and biological architecture of adult human height. Nat Genet 2014; 
46: 1173–86.  
21  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC 
investigators. Am J Epidemiol 1989; 129: 687–702.  
22  Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, 
Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and 
rationale. Ann Epidemiol 1991; 1: 263–76.  
23  Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. 
Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal 
Investigation of Thromboembolism Etiology. Am J Med 2004; 117: 19–25.  
24  Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular 
risk factors and venous thromboembolism incidence: the Longitudinal Investigation of 
Thromboembolism Etiology. Arch Intern Med 2002; 162: 1182–9.  
25  Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, DE Andrade M. Genetic 
variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways 
as risk factors for venous thromboembolism. J Thromb Haemost 2011; 9: 1133–42.  
23 
 
26  Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi 
J, Van Lente F, Zhang YL, Coresh J, Levey AS, CKD-EPI Investigators. Estimating 
glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20–
9.  
27  Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality 
assurance in the Cardiovascular Health Study. Clin Chem 1995; 41: 264–70.  
28  Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of 
hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in 
Communities (ARIC) Study. Circulation 1997; 96: 1102–8.  
29  Folsom AR, Lutsey PL, Roetker NS, Rosamond WD, Lazo M, Heckbert SR, Basu S, 
Cushman M, Selvin E. Elevated hepatic enzymes and incidence of venous 
thromboembolism: a prospective study. Ann Epidemiol 2014; 24: 817–821.e2.  
30  Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in 
healthy subjects: implications for reference intervals and epidemiological applications. Clin 
Chem 1997; 43: 52–8.  
31  Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, 
Harris TB, Witteman JCM, Boerwinkle E, CHARGE Consortium. Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective 
meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 
2009; 2: 73–80.  
24 
 
32  Tang W, Teichert M, Chasman DI, Heit JA, Morange P-E, Li G, Pankratz N, Leebeek FW, 
Paré G, de Andrade M, Tzourio C, Psaty BM, Basu S, Ruiter R, Rose L, Armasu SM, 
Lumley T, Heckbert SR, Uitterlinden AG, Lathrop M, et al. A genome-wide association 
study for venous thromboembolism: the extended Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) Consortium. Genet Epidemiol 2013; 37: 512–21.  
33  Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, Petterson TM, De 
Andrade M. A genome-wide association study of venous thromboembolism identifies risk 
variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012; 10: 1521–31.  
34  Li Y, Willer C, Sanna S, Abecasis G. Genotype Imputation. Annu Rev Genomics Hum Genet 
2009; 10: 387–406.  
35  Servin B, Stephens M. Imputation-based analysis of association studies: candidate regions 
and quantitative traits. PLoS Genet 2007; 3: e114.  
36  Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for 
Mendelian randomization. Stat Methods Med Res 2015; .  
37  Clarke PS, Palmer TM, Windmeijer F. Estimating structural mean models with multiple 
instrumental variables using the generalised method of moments. Stat Sci 2015; 30: 96–117.  
38  Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: 




39  Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian 
Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet 
Epidemiol 2016; 40: 304–14.  
40  Palmer TM, Sterne JAC, Harbord RM, Lawlor DA, Sheehan NA, Meng S, Granell R, Smith 
GD, Didelez V. Instrumental variable estimation of causal risk ratios and causal odds ratios 
in Mendelian randomization analyses. Am J Epidemiol 2011; 173: 1392–403.  
41  Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian 
randomisation studies with summary data and a continuous outcome. Stat Med 2015; 34: 
2926–40.  
42  Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational 
studies using “Mendelian triangulation” by Bautista et al. Ann Epidemiol 2007; 17: 511–3.  
43  StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.  
44  R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 
R Foundation for Statistical Computing; 2015.  
45  Staiger D, Stock JH. Instrumental Variables Regression with Weak Instruments. 
Econometrica 1997; 65: 557–86.  
46  de Haan HG, Bezemer ID, Doggen CJM, Le Cessie S, Reitsma PH, Arellano AR, Tong CH, 
Devlin JJ, Bare LA, Rosendaal FR, Vossen CY. Multiple SNP testing improves risk 
prediction of first venous thrombosis. Blood 2012; 120: 656–63.  
26 
 
47  Rosenberg MA, Patton KK, Sotoodehnia N, Karas MG, Kizer JR, Zimetbaum PJ, Chang JD, 
Siscovick D, Gottdiener JS, Kronmal RA, Heckbert SR, Mukamal KJ. The impact of height 
on the risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 2012; 33: 
2709–17.  
48  Tang W, Yao L, Roetker NS, Alonso A, Lutsey PL, Steenson CC, Lederle FA, Hunter DW, 
Bengtson LGS, Guan W, Missov E, Folsom AR. Lifetime risk and risk factors for abdominal 
aortic aneurysm in a 24-year prospective study: the ARIC Study (Atherosclerosis Risk in 
Communities). Arterioscler Thromb Vasc Biol 2016; 36: 2468–77.  
49  Nüesch E, Dale C, Palmer TM, White J, Keating BJ, van Iperen EP, Goel A, Padmanabhan 
S, Asselbergs FW, EPIC-Netherland Investigators, Verschuren WM, Wijmenga C, Van der 
Schouw YT, Onland-Moret NC, Lange LA, Hovingh GK, Sivapalaratnam S, Morris RW, 
Whincup PH, Wannamethe GS, et al. Adult height, coronary heart disease and stroke: a 
multi-locus Mendelian randomization meta-analysis. Int J Epidemiol 2015; .  
50  Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, Kanoni S, 
Willenborg C, Burgess S, Amouyel P, Anand S, Blankenberg S, Boehm BO, Clarke RJ, 
Collins R, Dedoussis G, Farrall M, Franks PW, Groop L, Hall AS, et al. Genetically 
determined height and coronary artery disease. N Engl J Med 2015; 372: 1608–18.  
51  Mammen EF. Pathogenesis of Venous Thrombosis. Chest 1992; 102: 640S–644S.  
52  Cushman M, O’Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size 
measures, hemostatic and inflammatory markers and risk of venous thrombosis: The 
Longitudinal Investigation of Thromboembolism Etiology. Thromb Res 2016; 144: 127–32.  
27 
 
53  Wirén S, Häggström C, Ulmer H, Manjer J, Bjørge T, Nagel G, Johansen D, Hallmans G, 
Engeland A, Concin H, Jonsson H, Selmer R, Tretli S, Stocks T, Stattin P. Pooled cohort 
study on height and risk of cancer and cancer death. Cancer Causes Control 2014; 25: 151–
9.  
54  Kügler C, Strunk M, Rudofsky G. Venous pressure dynamics of the healthy human leg. Role 
of muscle activity, joint mobility and anthropometric factors. J Vasc Res 2001; 38: 20–9.  
55  Karino T, Motomiya M. Flow through a venous valve and its implication for thrombus 
formation. Thromb Res 1984; 36: 245–57.  
56  Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference 
in epidemiological studies. Hum Mol Genet 2014; 23: R89-98.  
57  Bezemer ID, Bare LA, Doggen CJM, Arellano AR, Tong C, Rowland CM, Catanese J, 
Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein 
thrombosis. JAMA 2008; 299: 1306–14.  
58  Trégouët D-A, Heath S, Saut N, Biron-Andreani C, Schved J-F, Pernod G, Galan P, Drouet 
L, Zelenika D, Juhan-Vague I, Alessi M-C, Tiret L, Lathrop M, Emmerich J, Morange P-E. 
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci 
to VTE risk: results from a GWAS approach. Blood 2009; 113: 5298–303.  
59  Germain M, Saut N, Greliche N, Dina C, Lambert J-C, Perret C, Cohen W, Oudot-Mellakh 
T, Antoni G, Alessi M-C, Zelenika D, Cambien F, Tiret L, Bertrand M, Dupuy A-M, 
Letenneur L, Lathrop M, Emmerich J, Amouyel P, Trégouët D-A, et al. Genetics of venous 
thrombosis: insights from a new genome wide association study. PloS One 2011; 6: e25581.  
28 
 
60  Hernán MA, Robins JM. Instruments for causal inference: an epidemiologist’s dream? 
Epidemiology 2006; 17: 360–72.  
61  Bezemer ID, van der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The value of 
family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610–5.  
62  Zöller B, Li X, Sundquist J, Sundquist K. Age- and gender-specific familial risks for venous 
thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden. 
Circulation 2011; 124: 1012–20.  
 
